marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2024-Q2
added 08-05-2024
CRISPR Therapeutics AG Cash Flow 2011-2024 | CRSP
Annual Cash Flow CRISPR Therapeutics AG
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
-260 M | -496 M | 539 M | -238 M | 56.7 M | -96.2 M | -70.1 M | -52.9 M | - | - | - | - | - |
Depreciation & Amortization |
19.8 M | 24.2 M | 18 M | 9.18 M | 4.72 M | 3.52 M | 3.02 M | 925 K | 127 K | 38 K | - | - | - |
Accounts Payables |
38.1 M | 27.4 M | 14.8 M | 9.09 M | 5.94 M | 5.07 M | 1.64 M | 4.57 M | - | - | - | - | - |
Accounts Receivables |
200 M | - | 305 K | 144 K | 99 K | 88 K | 2.63 M | 3.16 M | - | - | - | - | - |
Total Inventories |
- | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Quarterly Cash Flow CRISPR Therapeutics AG
| 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Operating Cash Flow |
- | 110 M | - | - | - | 8.8 M | - | -382 M | -277 M | -135 M | - | 625 M | 706 M | -101 M | - | -157 M | -81.5 M | -52.2 M | - | 53.3 M | -80.1 M | -43.7 M | - | -67.9 M | -47.9 M | -22.7 M | - | -55.3 M | -39.4 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Depreciation & Amortization |
4.8 M | 4.83 M | - | 4.9 M | 5 M | 5.05 M | - | 5 M | 7.3 M | 6 M | - | 11.7 M | 6.37 M | 2.72 M | - | 6.62 M | 4.28 M | 2.09 M | - | 3.29 M | 2.01 M | 812 K | - | 2.57 M | 1.69 M | 826 K | - | 2.22 M | 1.43 M | 720 K | - | 513 K | 277 K | 106 K | - | 68 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Payables |
9.45 M | 16.5 M | 38.1 M | 26.2 M | 27.6 M | 45.2 M | 27.4 M | 32.1 M | 25.2 M | 27.1 M | 14.8 M | 10.2 M | 10.1 M | 13.1 M | 9.09 M | 9.09 M | 9.09 M | 9.09 M | 5.94 M | 5.94 M | 5.94 M | 5.94 M | 5.07 M | 5.07 M | 5.07 M | 5.07 M | 1.64 M | 1.64 M | 1.64 M | 1.64 M | 4.57 M | 4.57 M | 4.57 M | 4.57 M | 1.58 M | 1.58 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Accounts Receivables |
- | - | 200 M | - | 70 M | - | - | 49 K | 66 K | 143 K | 305 K | 152 K | 150 K | 150 K | 144 K | 144 K | 144 K | 144 K | 99 K | 99 K | 99 K | 99 K | 88 K | 88 K | 88 K | 88 K | 2.63 M | 2.63 M | 2.63 M | 2.63 M | 3.16 M | 3.16 M | 3.16 M | 3.16 M | 339 K | 339 K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Inventories |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency